Lobuxal is under clinical development by Laboratorios Silanes and currently in Phase III for Neuropathic Pain (Neuralgia). According to GlobalData, Phase III drugs for Neuropathic Pain (Neuralgia) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Lobuxal’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lobuxal overview
A fixed dose combination of pregabalin and tramadol is under development for the treatment of acute neuropathic pain. Pregabalin acts by targeting alpha2-delta type-1 subunit of voltage dependent calcium channel and and tramadol acts by targeting mu-opioid receptor. The drug combination is administered through oral route.
Laboratorios Silanes overview
Laboratorios Silanes is a manufacturer and supplier of pharmaceutical products. The company’s portfolio includes a broad range of analgesics, products for neurological disorders, metabolic diseases, tuberculosis, pain, asthma, and oral anti-diabetics. It also offers diagnostics and nutraceutical solutions. Through its subsidiary, Instituto Bioclon SA de CV, the company offers antivenom products. Laboratorios Silanes conducts research to develop generics for captopril, lysine clonixinate, enalapril, and carbamazepine, among others; and develop antibody based products and therapeutic peptides for the treatment of ocular, neurodegenerative, inflammatory, autoimmune, and infectious diseases and diabetes. The company licensed the development of glimepiride and metformin to its commercial partner, Sanofi. Laboratorios Silanes is headquartered in Mexico City, Mexico.
For a complete picture of Lobuxal’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
